Cargando…
Metabotropic Glutamate Receptors for Parkinson's Disease Therapy
Excessive glutamatergic signalling within the basal ganglia is implicated in the progression of Parkinson's disease (PD) and inthe emergence of dyskinesia associated with long-term treatment with L-DOPA. There is considerable research focus on the discovery and development of compounds that mod...
Autores principales: | Gasparini, Fabrizio, Di Paolo, Thérèse, Gomez-Mancilla, Baltazar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3703788/ https://www.ncbi.nlm.nih.gov/pubmed/23853735 http://dx.doi.org/10.1155/2013/196028 |
Ejemplares similares
-
Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease
por: Duty, Susan
Publicado: (2010) -
Therapeutic promise and principles: Metabotropic glutamate receptors
por: Maiese, Kenneth, et al.
Publicado: (2008) -
Metabotropic glutamate receptors inhibit microglial glutamate release
por: McMullan, Stephen M, et al.
Publicado: (2012) -
Optical Control of Metabotropic Glutamate Receptors
por: Levitz, Joshua, et al.
Publicado: (2013) -
Kinetic fingerprinting of metabotropic glutamate receptors
por: Kukaj, Taulant, et al.
Publicado: (2023)